Results 21 to 30 of about 247,168 (212)

Interleukin-15 After Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response Against Syngeneic Mouse Tumors [PDF]

open access: yesCancers, 2020
Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by 690 nm light.
Hiroaki Wakiyama   +2 more
exaly   +3 more sources

Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin

open access: yesCells, 2020
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable.
Yuko Nishinaga   +17 more
doaj   +2 more sources

Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment [PDF]

open access: yesScientific Reports, 2022
Cancer-associated fibroblasts (CAFs) play a significant role in tumor progression within the tumor microenvironment. Previously, we used near-infrared photoimmunotherapy (NIR-PIT), a next-generation cancer cell-targeted phototherapy, to establish CAF ...
Hiroaki Sato   +17 more
doaj   +2 more sources

Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.

open access: yesPLoS ONE, 2015
AimTriple-negative breast cancer (TNBC) is considered one of the most aggressive subtypes of breast cancer. Near infrared photoimmunotherapy (NIR-PIT) is a cancer treatment that employs an antibody-photosensitizer conjugate (APC) followed by exposure of ...
Tadanobu Nagaya   +5 more
doaj   +2 more sources

Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms [PDF]

open access: yesRSC Chemical Biology
Near-infrared photoimmunotherapy (NIR-PIT) is an innovative cancer treatment modality that was approved in Japan in 2020 for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.
Yoshikazu Fuse   +4 more
doaj   +2 more sources

Combined CD25-targeted near infrared photoimmunotherapy (NIR-PIT) and intratumor IL-15 enhance the effectiveness of anti-PD-1 immunotherapy [PDF]

open access: yesCancer Immunology, Immunotherapy
Immunotherapies aimed at enhancing anti-cancer immunity are now in wide clinical use. For instance, anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) therapy has demonstrated clinical efficacy in many tumor types, but overall, only a ...
Makoto Kano   +10 more
doaj   +2 more sources

Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer [PDF]

open access: yesBMC Cancer
Background Human epidermal growth factor receptor 3 (HER3), a member of the HER/ErbB family, is broadly expressed across major breast cancer subtypes and contributes to tumor initiation, progression, and therapy resistance.
Makoto Kano   +10 more
doaj   +2 more sources

Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma

open access: yesEJC Paediatric Oncology
Introduction: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that specifically targets cancer cells. In NIR-PIT, antibody-photo-absorber-conjugates (APCs), specific for cancer antigens, target cancer cells.
Jimei Zhao   +7 more
doaj   +2 more sources

Adding Intratumoral Antibody-Photoabsorber Conjugate Improves Efficacy of Near-Infrared Photoimmunotherapy (NIR-PIT). [PDF]

open access: yesCancer Sci
Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer treatment that specifically kills target cells while sparing normal tissue. This treatment induces cancer cell death by activating a photoreactive dye with near‐infrared light in an ...
Kano M   +9 more
europepmc   +3 more sources

Near-infrared photoimmunotherapy for osteosarcoma targeting epidermal growth factor receptor

open access: yesTranslational Oncology
Osteosarcoma is the most common bone tumor, and it possesses high metastatic propensity. Although systemic chemotherapy has improved its prognosis, improvements in survival rates have stalled in recent years.
Motofumi Suzuki   +2 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy